Clinical Trial: Phase 3 Study of ALXN1850 in Treatment-Na�ve Pediatric Participants With HPP

Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL

Official Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 Years of

Brief Summary: The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.

Detailed Summary:
Sponsor: Alexion Pharmaceuticals, Inc.

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Alexion Pharmaceuticals, Inc.

Dates:
Date Received: October 06, 2023
Date Started: January 01, 2024
Date Completion: January 01, 2024
Last Updated: December 11, 2023
Last Verified: December 01, 2023